Rare disease market assessments frequently begin with prevalence.
They should not end there.
A population estimate can describe how many people may live with a condition.
It does not describe how many patients can realistically receive therapy.
For commercial strategy, that distinction is fundamental.
The Prevalence Funnel
Leadership should separate:
Total prevalence
How many people may have the disease?
Diagnosed prevalence
How many know they have it?
Clinically eligible population
How many meet treatment criteria?
Addressable population
How many can realistically be reached?
Accessible population
How many can obtain treatment?
Treated population
How many ultimately initiate therapy?
Each transition can materially reduce the opportunity. Related: biotech market opportunity assessment framework.
Diagnostic Delay
Rare disease diagnosis may require multiple physicians, specialist referrals or specific testing.
Every delay changes the near-term commercial market.
A therapy can address a serious unmet need while the company still struggles to identify eligible patients.
Commercial planning should therefore understand diagnostic behavior as deeply as prevalence. Related: U.S. rare disease launch strategy.
Geography and Treatment Concentration
Patients may be geographically dispersed while clinical expertise is highly concentrated.
That creates an unusual commercial architecture.
A small number of institutions or specialists may influence a large proportion of treatment decisions.
Understanding those networks can be more valuable than simply identifying patient density. Related: Centers of Excellence.
Referral Leakage
The patient journey often contains points where patients are lost:
- Symptoms are misinterpreted.
- Referral does not occur.
- Testing is delayed.
- Patients reach the wrong specialist.
- Diagnosis occurs but treatment does not.
- Access fails after prescription.
Commercial strategy should identify those points explicitly. Related: patient journey mapping.
Access Further Reduces the Market
Even a correctly diagnosed and eligible patient may experience:
- coverage restrictions;
- prior authorization;
- specialty pharmacy delays;
- financial burden;
- treatment-site challenges.
The commercially addressable population therefore represents the interaction between epidemiology, diagnosis, treatment behavior and access.
Why This Matters for Forecasting
If prevalence is treated as the commercial market, forecasting assumptions can become structurally optimistic.
That affects more than revenue forecasts.
It can influence:
- company valuation;
- organization size;
- field-force investment;
- inventory;
- patient services;
- marketing spend;
- board expectations.
Better market understanding leads to better capital allocation.
The Commercial Question
Instead of asking only:
How many people have the disease?
Leadership should ask:
How many appropriate patients can realistically be identified, diagnosed, accessed and treated—and what must change to increase that number?
That is the market PharmaKonsult would use to begin commercial strategy.
Discuss Rare Disease Commercialization
Speak with PharmaKonsult about rare disease market opportunity, patient identification and U.S. launch strategy.
